Getinge (GETI) Morgan Stanley 24th Annual Global Healthcare Conference summary

Business transformation and operational improvements

• Significant progress in quality management, with most products now fully compliant and only two key 510(k)s pending approval.

• Enhanced compliance and operational structure have led to improved margins and a more robust business.

• Company culture has shifted to a long-term focus, emphasizing continuous improvement and customer service.

Regional market outlooks

• U.S. hospital CapEx demand remains robust, especially for OR productivity and patient outcomes.

• EMEA continues to show strong momentum, with Germany as a standout, though growth may moderate from Q2 highs.

• China remains challenging due to macro, competitive, and local content pressures, but growth is expected to align with the market at around 5% as conditions stabilize.

Segment performance and product innovation

• Life science order intake is strong, especially in the Americas, with bioprocessing and sterile transfer showing growth, though pharma CapEx decisions are delayed by geopolitical uncertainty.

• Acute care therapies rebounded from a sales decline to 6% growth, driven by new product launches like Cardiohelp II and stable procedure volumes.

• Cardiohelp II is now in full launch, expected to expand the install base and consumables demand, with a 510(k) submission for the U.S. on track for H2 2026.